Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
Authors
Keywords
Targeted alpha therapy, <sup>213</sup>Bi-DOTATATE, Nephrotoxicity, Maximum tolerated dose, <span class=EmphasisTypeSmallCaps >l
Journal
EJNMMI Research
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-21
DOI
10.1186/s13550-016-0240-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
- (2016) Ho Sze Chan et al. EJNMMI Research
- Biomarkers of renal function, which and when?
- (2015) Michael E. Wasung et al. CLINICA CHIMICA ACTA
- Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
- (2015) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Utilizing High-Energy -Photons for High-Resolution 213Bi SPECT in Mice
- (2015) J. de Swart et al. JOURNAL OF NUCLEAR MEDICINE
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
- (2014) C. Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
- (2014) Lisa Bodei et al. Thoracic Surgery Clinics
- Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody
- (2013) H. Song et al. MOLECULAR CANCER THERAPEUTICS
- Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy
- (2012) Peter Kletting et al. MEDICAL PHYSICS
- A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
- (2012) Robert F Hobbs et al. PHYSICS IN MEDICINE AND BIOLOGY
- Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
- (2011) D. Wild et al. CANCER RESEARCH
- Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides
- (2010) Erik de Blois et al. APPLIED RADIATION AND ISOTOPES
- Neutrophil Gelatinase–Associated Lipocalin (NGAL) as a Marker of Kidney Damage
- (2008) Davide Bolignano et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury
- (2008) P. Devarajan NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search